PMID- 35357748
OWN - NLM
STAT- MEDLINE
DCOM- 20220622
LR  - 20220622
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 21
IP  - 6
DP  - 2022 Jun
TI  - Evaluation of the long-term safety and biodegradability of hyaluronic acid dermal 
      fillers (YVOIRE((R)) ) for the correction of nasolabial folds: Two multicenter, 
      prospective, observational cohort studies.
PG  - 2387-2397
LID - 10.1111/jocd.14952 [doi]
AB  - BACKGROUND: The therapeutic effects of hyaluronic acid dermal fillers to correct 
      facial wrinkles and folds usually last up to 6-12 months. Few studies have 
      evaluated their long-term safety. AIMS: To evaluate the long-term safety and 
      biodegradability of two hyaluronic acid dermal fillers (YVOIRE((R)) classic s and 
      YVOIRE((R)) volume s) for the correction of nasolabial folds (NLFs) in two 
      prospective, observational studies. METHODS: Subjects scheduled to receive the 
      injections of YVOIRE((R)) classic s (N = 503) or YVOIRE((R)) volume s (N = 503) at 
      NLFs were followed up until complete clinical biodegradation, defined as a change 
      in Wrinkle Severity Rating Scale (WSRS) score of >/=0 from baseline. The primary 
      biodegradation endpoint was the proportion of subjects with complete clinical 
      biodegradation during or after the 104-week post-treatment period. RESULTS: 
      Complete clinical biodegradation was observed in 93.5% [95% CI 91.0%-95.5%] of 
      494 assessable YVOIRE((R)) classic s recipients and 98.5% [95% CI 97.0%-99.4%] of 
      469 YVOIRE((R)) volume s recipients during the 104-week post-treatment period. In 
      most subjects, complete clinical biodegradation was observed within 52 weeks of 
      the last treatment. Treatment-related adverse events (AEs) (mostly mild local 
      injection-site reactions) occurred within 52 weeks post-treatment, in 68.2% and 
      75.0% of YVOIRE((R)) classic s and YVOIRE((R)) volume s recipients, respectively. 
      During the 12 to 18 months after YVOIRE((R)) volume s injection, 0.6% of subjects 
      had treatment-related AEs (local injection-site reactions). No treatment-related 
      AEs occurred 12 to 24 months after YVOIRE((R)) classic s injection. CONCLUSIONS: 
      YVOIRE((R)) classic s and YVOIRE((R)) volume s can be safely used to correct NLFs. 
      Total clinical biodegradation tends to occur within 12 months of injection.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Xie, Yun
AU  - Xie Y
AD  - Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Wu, Sufan
AU  - Wu S
AD  - Zhejiang Provincial People's Hospital, Hangzhou, China.
FAU - Li, Shirong
AU  - Li S
AD  - Southwest Hospital, Third Military Medical University, Chongqing, China.
FAU - Li, Qingfeng
AU  - Li Q
AD  - Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Zhao, Hongyi
AU  - Zhao H
AD  - Beijing Hospital, Ministry of Health, Beijing, China.
LA  - eng
GR  - LG Chem, Ltd./
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20220509
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Dermal Fillers)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - *Cosmetic Techniques/adverse effects
MH  - *Dermal Fillers
MH  - Humans
MH  - Hyaluronic Acid
MH  - Injection Site Reaction/etiology
MH  - Nasolabial Fold
MH  - Prospective Studies
MH  - *Skin Aging
MH  - Treatment Outcome
OTO - NOTNLM
OT  - YVOIRE(R) classic s
OT  - YVOIRE(R) volume s
OT  - biodegradability
OT  - hyaluronic acid
OT  - nasolabial folds
OT  - safety
EDAT- 2022/04/01 06:00
MHDA- 2022/06/23 06:00
CRDT- 2022/03/31 12:07
PHST- 2022/02/20 00:00 [revised]
PHST- 2021/06/26 00:00 [received]
PHST- 2022/03/28 00:00 [accepted]
PHST- 2022/04/01 06:00 [pubmed]
PHST- 2022/06/23 06:00 [medline]
PHST- 2022/03/31 12:07 [entrez]
AID - 10.1111/jocd.14952 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2022 Jun;21(6):2387-2397. doi: 10.1111/jocd.14952. Epub 2022 
      May 9.